Health sciences

 UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Chemical compounds, Health sciences, Organic compounds, Orphan drugs, Breakthrough therapy, Aziridines, Cancer treatments, Mitomycin C, Oncology, Fast track, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UGN-102, the Phase 3 ATLAS Trial, UroGen Pharma Ltd., JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UGN-102, THE PHASE 3 ATLAS TRIAL, UROGEN PHARMA LTD.

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005328/en/

NMPA’s Center for Drug Evaluation Adds Licenses of GastroPlus®

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Health, Pharmaceutical, Technology, Software, Simulation software, Simulations Plus, Health sciences, Pharmacokinetics, NMPA, National Medical Products Administration, Simulation, Bioequivalence, Life sciences, Health

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has received an order from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China to add licenses to GastroPlus.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has received an order from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China to add licenses to GastroPlus.
  • We have cultivated relationships with different affiliated institutions of NMPA to apply our technology to support the evaluation of drug product specifications and bioequivalence.
  • Now, researchers at the CDE will add GastroPlus to serve as a key platform for model-informed drug development (MIDD) to aid regulatory reviews.
  • Serving clients worldwide for 25 years, Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions.

Fist Assist Devices, LLC Announces Completion of the Non-Significant Risk FACT Trial

Retrieved on: 
Wednesday, August 4, 2021
Health, Clinical Trials, Medical Supplies, Medical Devices, Health sciences, Health, Clinical pharmacology, Clinical research, Clinical trial, Design of experiments, Food and Drug Administration, Pharmaceutical industry

Fist Assist Devices, LLC, announces completion of the non-significant risk FACT Trial (Fist Assist Clinical Trial).

Key Points: 
  • Fist Assist Devices, LLC, announces completion of the non-significant risk FACT Trial (Fist Assist Clinical Trial).
  • This is a landmark, global trial evaluating the effectiveness of the FA-1 intermittent compression device on pre-surgery, stage 4 chronic renal failure patients.
  • Fist Assist Devices is a privately held company from Silicon Valley, California that has developed the Fist Assist technology over the past 30 years.
  • The Fist Assist FA-1 device is distributed in India via an alliance with Medifocus ( http://medifocusindia.com ) and in the United States via an alliance with AIROS Medical, Inc. ( www.airosmedical.com )
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005188/en/

Better Therapeutics, Inc. to Present at the Canaccord Genuity’s 41st Annual Growth Conference

Retrieved on: 
Wednesday, August 4, 2021
Mental Health, Mobile, Wireless, Technology, Diabetes, Cardiology, Software, Other Health, Biotechnology, General Health, Health, Health sciences, Medicine, Articles, Health informatics, Behavior modification, Digital therapeutics, Addiction, Addiction medicine, Genuity, Therapy, Cognitive behavioral therapy, Disease, Better Therapeutics, Mountain Crest Acquisition Corp. II, BETTER THERAPEUTICS, MOUNTAIN CREST ACQUISITION CORP. II

Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.

Key Points: 
  • Better Therapeutics, Inc. (Better Therapeutics), a prescription digital therapeutics company delivering cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced its team is participating in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021.
  • The cognitive behavioral therapy delivered by Better Therapeutics PDTs enables changes in neural pathways of the brain so lasting changes in behavior become possible.
  • Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs.
  • Better Therapeutics clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

Virtual Care Company LetsGetChecked Announces Acquisition Of Florida-Based Pharmacy

Retrieved on: 
Wednesday, August 4, 2021
Medical Devices, Health, Technology, Mobile, Wireless, General Health, Pharmaceutical, Health sciences, Pharmacy, Medicinal chemistry, Symbols, Health care, Pharmaceutical sciences

LetsGetChecked, a leading virtual care company, announced today the acquisition of a Florida-based pharmacy.

Key Points: 
  • LetsGetChecked, a leading virtual care company, announced today the acquisition of a Florida-based pharmacy.
  • LetsGetChecked will use the new pharmacy acquisition to expand its consumer reach and eventually provide pharmaceutical services to customers nationwide.
  • The brand has also disclosed plans to launch CarePathways, a 360-degree customer care journey that will provide remote care for patients with ailments and chronic conditions.
  • Founded in 2015, the company empowers people with the care they need to live longer, happier lives.

Biotech Founder, Monzer Hourani, Calls for Urgent Action in Open Letter to President Biden: "We cannot be afraid to 'follow the science,' a solution of many requires bold decisions."

Retrieved on: 
Wednesday, August 4, 2021
Clinical trials, Medicine, Medical specialties, Health sciences, Vaccine, COVID-19 vaccine

The IVP science is based on a patent-pending design to disinfect the air using heat--"catching and killing" actual SARS-CoV-2 and other submicron airborne pathogens, including anthrax spores, instantaneously, without impacting the ambient air temperature. The Biodefense Air Protection System is installed into air conditioners and mobile units providing anti-viral and cleaning power to all indoor pollutants, molds, pollen etc. The filters provide a scientific advantage to any HVAC filter on the market, including HEPA, which is not effective in killing any airborne pathogens. In turn, IVP helps the energy efficiency and sustainability of our buildings, schools, and healthcare facilities. 

Key Points: 
  • Do we really know what it is to be immune from COVID-19, and for how long will we be protected by the bioscience of a vaccine?
  • We cannot be afraid to 'follow the science' a solution of many requires bold decisions," Hourani stated, in his cry for help from President Biden and his administration.
  • Houston-based Integrated Viral Protection, LLC (IVP) is a biotech company formed to promote anti-COVID-19 technology based on engineering and science.
  • The technology has received certifications for safety and effectiveness, as well as meeting FDA guidelines for sale during the COVID-19 pandemic.

RXNT Named "Best E-Prescribing Software" of 2021

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Health, Medicine, Medical terminology, Health informatics, Pharmacy, Electronic prescribing, Patient safety, Symbols, Medical prescription

ANNAPOLIS, Md., Aug. 4, 2021 /PRNewswire-PRWeb/ -- RXNT , an industry-leading provider of cloud-based ambulatory healthcare software, today announced that it has been selected as one of the Best E-Prescribing Software companies of 2021 by Digital.com, an independent review website for small businesses and startups.

Key Points: 
  • ANNAPOLIS, Md., Aug. 4, 2021 /PRNewswire-PRWeb/ -- RXNT , an industry-leading provider of cloud-based ambulatory healthcare software, today announced that it has been selected as one of the Best E-Prescribing Software companies of 2021 by Digital.com, an independent review website for small businesses and startups.
  • The research team conducted over 40 hours of assessment on more than 75 e-prescribing software companies from across the web to create the report.
  • "We are excited to once again stand out as a leader in the growing and evolving HealthIT market," said Randy Boldyga, CEO and President of RXNT.
  • RXNT was recognized based on its core features like medication history, clinical alerts, prescription cancellation and renewals, and refill management.

SciSparc Announces Completion of Corporate Rebranding and Launch of New Website

Retrieved on: 
Wednesday, August 4, 2021
Clinical research, Design of experiments, Health sciences, Health, Medical research, Clinical trial, Drug discovery, Pharmaceutical industry, Placebo-controlled study, Draft:PPP001, Tcelna

The Company recently provided an update on its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment, SCI-110.

Key Points: 
  • The Company recently provided an update on its Phase IIb clinical study in Tourette Syndrome using the proprietary cannabinoid-based treatment, SCI-110.
  • SciSparc intends to evaluate the efficacy, safety and tolerability of its SCI-110 in a randomized, double-blind, placebo controlled, cross-over study.
  • "We believe this rebranding and new website reflect SciSparc's vision and dedication to the development of cannabinoid-based treatments."
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

Catalyst Cannabis Co. Establishes First Private Sector Social Equity Incubator Pusherman Delivery

Retrieved on: 
Wednesday, August 4, 2021
Herbalism, Medicinal plants, Health sciences, Medicine, Clinical medicine, Cannabis smoking, Cannabis, Entheogens, Medical cannabis

LONG BEACH, Calif., August 4, 2021 /PRNewswire-PRWeb/ -- Catalyst Cannabis Co. , a leading California-based cannabis retailer is pleased to announce the opening of their first private sector social equity incubator, Pusherman Delivery .

Key Points: 
  • LONG BEACH, Calif., August 4, 2021 /PRNewswire-PRWeb/ -- Catalyst Cannabis Co. , a leading California-based cannabis retailer is pleased to announce the opening of their first private sector social equity incubator, Pusherman Delivery .
  • Co-founded by Carlos Zepeda, Pusherman Delivery marks the first and only social equity applicant run cannabis delivery business in Long Beach, CA and is one of the few private sector funded social equity incubators in the industry.
  • To make Pusherman Delivery a reality, Catalyst Cannabis Co. put up their delivery licence under the Eastside Catalyst location along with funding 100% of the start-up costs, compliance and workforce training.
  • Pusherman's incubator model is meant to give social equity applicants a pathway to start a legitimate business in the cannabis space.

Ground-breaking Technology by Micellae, a University of Toronto Spinout, Set to Revolutionize Cannabinoid Delivery

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Life sciences, Pharmacology, Dosage forms, Pharmaceutical industry, Excipient, Pharmacy, Drug delivery, Self-microemulsifying drug delivery system, Bioavailability

TORONTO, Aug. 4, 2021 /PRNewswire/ -Micellae Delivery Systems Inc. ("Micellae") today announced the launch of its breakthrough drug delivery technology, O2W, the fastest oral bioavailability-enhancing formulation.

Key Points: 
  • TORONTO, Aug. 4, 2021 /PRNewswire/ -Micellae Delivery Systems Inc. ("Micellae") today announced the launch of its breakthrough drug delivery technology, O2W, the fastest oral bioavailability-enhancing formulation.
  • University of Toronto (U of T) Researcher and Micellae's Founder and CEO, Dr. Mehdi Nouraei, highlighted that,"Emulsification technologies have previously been employed in cannabinoid-based products.
  • However, existing technologies are less than optimal and result in significant compromises, including slow onset of action, complex manufacturing, unpleasant taste, and short shelf-life.
  • O2W is the only self-dispersing and fully water-dilutable Self-Microemulsifying Drug Delivery System (SMEDDS) made with food-grade excipients.